Table 3.

Clinical efficiency of epigenetic drugs agents in PTCL

Drug	Patients distribution	Response (ORR, DOR, CR)	Phase
Chidamide [54]	N = 79 PTCL-NOS (34%), ALCL (20%), ENKTL: (20%)	ORR:28% Median PFS: 2.1 months OS:21.4 months CR/Cru:14% Median DOR: 9.9 month	II
Chidamide-Combined Chemotherapy [56]	N = 127	ORR = 51.18% DCR = 74.02% Median PFS = 152 day	II
Chidamide [56]	N = 383 PTCL monotherapy (n = 256)	Monotherapy ORR = 39.06% DCR = 64.45%, median (PFS) = 129 days	II
Vorinostat [60] combination with chop	N = 14	Median PFS = 79% OS = 82% Median response duration = 29 months	I
Romidepsin [66, 67]	N = 130	ORR = 25% CR/Cru = 15% median PFS = 13.4 ~ 29 months. median DOR = 28 months	II
Romidepsin [68]	N = 47 PTCL	ORR = 38%,CR = 18% median DOR = 8.9 months	II
Romidepsin plus chop [70]	N = 37	ORR = 69% PFS = 41% OS = 71%,	Ib/II
Pralatrexate + Romidepsin [72]	N = 29	ORR = 71% (10/14)	II
Romidepsin [73]	N = 27 AITL	ORR = 33%
Belinostat [74]	N = 24 PTCL	ORR = 25%, CR = 8%, DOR = 13.6mo	II
Belinostat [75, 76]	N = 129	ORR (CR, PR) = 25.8% Median DoR = 13.6 months Median PFS = 1.6 months Median OS = 7.9 months	II
5-Azacytidine [125, 126]	N = 12	ORR = 75%, median PFS = 15 months median OS = 21 months	Clinic trial

AITL angioimmunoblastic T-cell lymphoma, PTCL peripheral T-cell lymphoma, Median PFS median progression-free survival, OS overall survival, DOR duration of response, Median DOR median duration of response, CR complete response, DCR disease control rate, PTCL-NOS PTCL not otherwise specified, ALCL anaplastic large-cell lymphoma, ENKTL extranodal natural killer (NK)/T-cell lymphoma, nasal type